Trusted Resources: Evidence & Education
Scientific literature and patient education texts
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events
source: The New England Journal of Medicine
year: 2016
authors: Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC
summary/abstract:BACKGROUND:
Sickle cell anemia is an inherited blood disorder that is characterized by painful vaso-occlusive crises, for which there are few treatment options. Platelets mediate intercellular adhesion and thrombosis during vaso-occlusion in sickle cell anemia, which suggests a role for antiplatelet agents in modifying disease events.
METHODS:
Children and adolescents 2 through 17 years of age with sickle cell anemia were randomly assigned to receive oral prasugrel or placebo for 9 to 24 months. The primary end point was the rate of vaso-occlusive crisis, a composite of painful crisis or acute chest syndrome. The secondary end points were the rate of sickle cell-related pain and the intensity of pain, which were assessed daily with the use of pain diaries.
RESULTS:
A total of 341 patients underwent randomization at 51 sites in 13 countries across the Americas, Europe, Asia, and Africa. The rate of vaso-occlusive crisis events per person-year was 2.30 in the prasugrel group and 2.77 in the placebo group (rate ratio, 0.83; 95% confidence interval, 0.66 to 1.05; P=0.12). There were no significant differences between the groups in the secondary end points of diary-reported events. The safety end points, including the frequency of bleeding events requiring medical intervention, of hemorrhagic and nonhemorrhagic adverse events that occurred while patients were taking prasugrel or placebo, and of discontinuations due to prasugrel or placebo, did not differ significantly between the groups.
CONCLUSIONS:
Among children and adolescents with sickle cell anemia, the rate of vaso-occlusive crisis was not significantly lower among those who received prasugrel than among those who received placebo. There were no significant between-group differences in the safety findings. (Funded by Daiichi Sankyo and Eli Lilly; ClinicalTrials.gov number, NCT01794000.).
DOI: 10.1056/NEJMoa1512021
read more full text
+myBinderRelated Content
-
Bluebird bio acquires Durham, NC, manufacturing site for lentiviral vector productionbluebird bio said today it has acquired ...
-
3 Gene Editing Approaches for Sickle Cell DiseaseSickle cell disease (SCD) is a perfect c...
-
High mortality among children with sickle cell anemia and overt stroke who discontinue blood transfusion after trans...BACKGROUND: Chronic blood transfusion is...
-
Vitamin D Supplements May Reduce Pain-related Emergency Room Visits in Children With SCDTaking vitamin D supplements may lower t...
-
Sickle Cell Breakthrough: Shauna’s Storyhttps://www.youtube.com/watch?v=Q-kXWV-s...
-
The use of cannabis by patients with sickle cell disease increased the frequency of hospitalization due to vaso-occl...Introduction: The objective of this stu...
-
Emmaus, a leader in sickle cell disease treatment, signs agreement with Cardinal Health to solidify distribution net...Emmaus Life Sciences, Inc. announces...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.